http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
홍삼추출액의 인간성체신경줄기세포 증식과 세포사 관련 세포주기의 변화에 대한 효과
김현정(Hyun-Jung Kim),강라미(Lami Kang),안진영(Jin Young Ahn),한정순(Jung Soon Han),김승업(Seung U. Kim),이광우(Kwang-Woo Lee),김만호(Manho Kim) 고려인삼학회 2004 Journal of Ginseng Research Vol.28 No.1
홍삼추출액의 신경성체줄기세포 성장과 생존에 미치는 영향을 분석하고자 human neuronal stem cell line인 F3 cell을 배양한 후 홍삼추출액을 여러 농도로 희석하여 MTT assay로 cell viability를 측정하였고 FACS analysis로 cell cycle변화를 측정하였다. 특정한 농도에서는 세포가 증식되는 경향을 보였으며 농도가 증가되면서 viability가 감소되는 현상을 확인할 수 있었다. Cell cycle분석상 세포증식시에는 S phase 및 G2/M phase가 증가되는 경향을 보였고, viability가 감소되면서 S phase가 감소되고 G0/G1 phase가 증가되었다. 한편 DNA fragmentation이 cell viability감소에 따라 증가되었으나, Caspase 3 activation 또는 Bax expression과는 관련성이 적었다. The present study is to determine whether the Red-ginseng extract has a proliferative or cytotoxic effect on the human neuronal stem cells(hNSCs). The hNSCs were grown and incubated with different doses of Red-ginseng extract. We tested the proliferative or cytotoxic effects by MTT and FACS analysis. Cell viability, cell cycle analysis, DNA fragmentation, and bax or PARP expressions were evaluated. The hNSCs showed a proliferatve trend with its peak concentration at 0.3㎍/㎖. Beyond this point, higher doses decreased viabilities and showed a cytotoxic effect at 10㎍/㎖. There was a tendency of increased S and G2/M phases during cell proliferation. In a cytotoxic condition, decreased S phase and increased G0/G1 phases were noted, suggesting cell cycle arrest. The cytotoxic effect was associated with increase DNA fragmentation in a dose-dependent manner. However, PARP cleavage or bax expression was not detected. Our results suggest that Red-ginseng extract has dual effects, the cell proliferative or cytotoxic effect, on hNSCs in vitro with dose-dependent manner.
불멸화 인간 태아 골수 유래 간엽줄기세포주의 제작 및 특성 연구
김우경 ( Woo Kyoung Kim ),박인호 ( In Ho Park ),( A. Nagai ),홍석호 ( Seok Ho Hong ),김광세 ( Kwang Sei Kim ),장윤경 ( Yun Kyung Jang ),김승업 ( Seung U. Kim ) 한국조직공학과 재생의학회 2005 조직공학과 재생의학 Vol.2 No.4
Bone marrow mesenchymal stem cells (MSCs) have multilineage differentiation capacity potential to become various cell types, including bone, cartilage, fat, muscle and neurons. MSCs have been engrafted and survived in animal grains, raising the possibility of therapeutic potential for patients with neurological disorders. Human fetal bone marrow MSCs were transfected with a retroviral vector carrying v-myc and twelve clones of human bone marrow MSC cell lines have been generated. B10, one of the cell lines, carries normal human karyotype of 46,XX and expresses cell type specific markers for human MSCs including CD13, CD29, CD44, CD49b, CD90 and CD166. when B10 cells were grown in differentiation media, better than 80% of cells differentiated into osteocytes, chondrocytes and adipocytes, and 40% of cells expressed neuron-specific cell type markers, beta-tubulin III and neurofilaments. These results indicate that the immortalized human MSCs should serve as a powerful tool for research into development of stem cell based therapy for human neurological disorders.
생쥐 뇌졸중 모델에서 불멸화 인간신경줄기세포주 이식에 의한 기능적 회복
이홍준 ( Hong Jun Lee ),박인호 ( In Ho Park ),김광세 ( Kwang Sei Kim ),정상욱 ( Sang Wuk Jeong ),김승업 ( Seung U. Kim ) 한국조직공학과 재생의학회 2005 조직공학과 재생의학 Vol.2 No.4
Cell replacement and gene transfer to the diseased or injured CNS have provided the basis for the development of powerful new cell based therapy for neurological diseases. An ideal source of cells for cell therapy is human neural stem cells (NSCs) that could integrate into host brain and differentiate into neurons or glial cells. We have recently generated stable, immortalized cell lines of human neural stem cells (NSCs) via retroviral vector encoding v-myc. Intracerebral hemorrhage (ICH) stroke models in adult mice were produced by intrastriatal injection of bacterial collagenase VII, and 1 week after the surgery the animals received intracerebral transplantation of following: (1) NSCs (HB1.F3), (2) PBS. Behavioral test (rota-rod motor, limb-placing test) demonstrated that the brain transplantation of human NSCs induced a significant improvement in motor function in animals after 2 weeks and on. Good survival of transplanted human NSCs was noted in the peri-hematomal area by X-gal staining and differentiated into neurons and astrocytes. Transplanted cells also showed BDNF, GDNF, and VEGF immunoreactivity. Our data suggest indicate that human NSC-based cell therapy could restore anatomic or functional deficits found in patients suffering with stroke.